Atlas Trials

Radiation Therapy Followed by Durvalumab (MEDI4736) and Tremelimumab And Surgery Versus Radiation Therapy Followed by Surgery for Resectable Hepatocellular Carcinoma.

Clinical trial NCT07027436 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07027436
Sponsor
Hamilton Health Sciences Corporation
Status
NOT_YET_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Hepatocellular Carcinoma (HCC)
Start date
2025-07-07
Primary completion
2027-10-12
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.